Health Research

Lymphoma (iNHL): A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)

Basic Study Information

Is the experimental product, KTE-C19, when administered after you receive a 3 day course of chemotherapy, safe and effective in treating your disease?
The sponsor is testing an experimental treatment named axicabtagene ciloleucel (KTE-C19), which uses the patient’s own genetically altered blood cells to treat cancer. KTE-C19 is made from white blood cells that are removed from the patient. A virus (retrovirus) is used to introduce a gene that creates a protein (called a chimeric antigen receptor or CAR) on the surface of T cells, a type of blood cell that fights infection and eliminates cancer cells. The hope is that the CAR on the T cells will bind to and kill cells that express CD19, a protein that is found on B-cell lymphomas.
Cancer Center

Lead Researcher (Principal Investigator)

Carla Casulo

Study Contact Information

Erin Enfield
(585) 276-4404

Learn More About These Conditions